Local ablation of pancreatic tumors: State of the art and future perspectives.
Ablation treatment
Electrochemotherapy
Irreversible
Microwave ablation
Pancreatic cancer
Radiofrequency ablation
Journal
World journal of gastroenterology
ISSN: 2219-2840
Titre abrégé: World J Gastroenterol
Pays: United States
ID NLM: 100883448
Informations de publication
Date de publication:
21 Jun 2021
21 Jun 2021
Historique:
received:
07
03
2021
revised:
28
03
2021
accepted:
08
05
2021
entrez:
24
6
2021
pubmed:
25
6
2021
medline:
29
6
2021
Statut:
ppublish
Résumé
Currently, the technologies most commonly used to treat locally advanced pancreatic cancer are radiofrequency ablation (RFA), microwave ablation, and irreversible (IRE) or reversible electroporation combined with low doses of chemotherapeutic drugs. To report an overview and updates on ablative techniques in pancreatic cancer. Several electronic databases were searched. The search covered the years from January 2000 to January 2021. Moreover, the reference lists of the found papers were analysed for papers not indexed in the electronic databases. All titles and abstracts were analysed. We found 30 studies (14 studies for RFA, 3 for microwave therapy, 10 for IRE, and 3 for electrochemotherapy), comprising 1047 patients, which were analysed further. Two randomized trials were found for IRE. Percutaneous and laparotomy approaches were performed. In the assessed patients, the median maximal diameter of the lesions was in the range of 2.8 to 4.5 cm. All series included patients unfit for surgical treatment, but Martin In the management of patients with pancreatic cancer, the possibility of a multimodal approach should be considered, and conceptually, the combination of RFA with immunotherapy represents a novel angle of attack against this tumour.
Sections du résumé
BACKGROUND
BACKGROUND
Currently, the technologies most commonly used to treat locally advanced pancreatic cancer are radiofrequency ablation (RFA), microwave ablation, and irreversible (IRE) or reversible electroporation combined with low doses of chemotherapeutic drugs.
AIM
OBJECTIVE
To report an overview and updates on ablative techniques in pancreatic cancer.
METHODS
METHODS
Several electronic databases were searched. The search covered the years from January 2000 to January 2021. Moreover, the reference lists of the found papers were analysed for papers not indexed in the electronic databases. All titles and abstracts were analysed.
RESULTS
RESULTS
We found 30 studies (14 studies for RFA, 3 for microwave therapy, 10 for IRE, and 3 for electrochemotherapy), comprising 1047 patients, which were analysed further. Two randomized trials were found for IRE. Percutaneous and laparotomy approaches were performed. In the assessed patients, the median maximal diameter of the lesions was in the range of 2.8 to 4.5 cm. All series included patients unfit for surgical treatment, but Martin
CONCLUSION
CONCLUSIONS
In the management of patients with pancreatic cancer, the possibility of a multimodal approach should be considered, and conceptually, the combination of RFA with immunotherapy represents a novel angle of attack against this tumour.
Identifiants
pubmed: 34163121
doi: 10.3748/wjg.v27.i23.3413
pmc: PMC8218359
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
3413-3428Informations de copyright
©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflict-of-interest statement: No conflict of interest.
Références
Int J Surg Case Rep. 2018;42:290-294
pubmed: 29335228
Gastrointest Endosc. 2016 Jan;83(1):234-9
pubmed: 26394384
Radiol Oncol. 2019 Jan 19;53(1):15-24
pubmed: 30681974
Ann Surg Oncol. 2013 Dec;20 Suppl 3:S443-9
pubmed: 23128941
Minim Invasive Ther Allied Technol. 2018 Feb;27(1):33-40
pubmed: 29278340
J Vasc Interv Radiol. 2014 Jul;25(7):997-1011; quiz 1011
pubmed: 24656178
Int J Surg. 2015 Jun;18:230-6
pubmed: 25917204
Chin Med J (Engl). 2016 20th Dec;129(24):2920-2925
pubmed: 27958223
Pancreas. 2017 Feb;46(2):e12-e14
pubmed: 28085755
Pancreas. 2014 Aug;43(6):938-45
pubmed: 24717825
Nanomedicine (Lond). 2014;9(8):1181-92
pubmed: 24024571
J Gastrointest Oncol. 2016 Apr;7(2):213-20
pubmed: 27034788
Dig Dis Sci. 2015 Nov;60(11):3449-55
pubmed: 26038094
HPB (Oxford). 2014 Feb;16(2):119-23
pubmed: 23600801
Radiol Med. 2014 Jul;119(7):483-98
pubmed: 24981482
J Vasc Interv Radiol. 2020 Oct;31(10):1600-1608
pubmed: 32861569
Radiol Med. 2014 Jul;119(7):449-50
pubmed: 25001586
Eur Radiol. 2017 Jun;27(6):2521-2531
pubmed: 27659702
Technol Cancer Res Treat. 2017 Jun;16(3):285-294
pubmed: 27193941
J Vasc Interv Radiol. 2012 Dec;23(12):1613-21
pubmed: 23177107
Radiol Med. 2015 Feb;120(2):180-9
pubmed: 24961341
Gastrointest Endosc. 2016 Feb;83(2):440-3
pubmed: 26344883
Ann Surg Oncol. 2020 Dec;27(Suppl 3):954-955
pubmed: 33011913
Radiol Med. 2015 Jul;120(7):641-54
pubmed: 25634793
Gland Surg. 2018 Apr;7(2):59-66
pubmed: 29770302
Ther Adv Med Oncol. 2020 Sep 10;12:1758835920953728
pubmed: 32973929
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
World J Gastroenterol. 2010 Oct 28;16(40):5104-10
pubmed: 20976848
Cancers (Basel). 2020 Feb 23;12(2):
pubmed: 32102182
Clin Colorectal Cancer. 2018 Sep;17(3):187-197
pubmed: 29615310
HPB (Oxford). 2013 Aug;15(8):623-7
pubmed: 23458679
J Vasc Interv Radiol. 2017 Mar;28(3):342-348
pubmed: 27993507
Endosc Ultrasound. 2020 Mar-Apr;9(2):83-100
pubmed: 32295966
Br J Surg. 2015 Feb;102(3):182-93
pubmed: 25524417
Cell Death Dis. 2020 Jul 27;11(7):589
pubmed: 32719347
Ann Palliat Med. 2021 Feb;10(2):1842-1850
pubmed: 33440967
Radiology. 2020 Jan;294(1):212-220
pubmed: 31687922
Neoplasma. 2016;63(2):269-73
pubmed: 26774149
Cancer Med. 2020 Jul;9(13):4699-4710
pubmed: 32410380
Cochrane Database Syst Rev. 2018 Mar 20;3:CD011044
pubmed: 29557103
Gastroenterol Res Pract. 2016;2016:4508376
pubmed: 26981115
HPB (Oxford). 2006;8(1):61-4
pubmed: 18333241
Ultraschall Med. 2020 Aug 14;:
pubmed: 32797463
Cureus. 2020 Oct 1;12(10):e10758
pubmed: 33150109
Onco Targets Ther. 2019 Feb 18;12:1341-1350
pubmed: 30863100
Ann Surg. 2021 Jun 1;273(6):1173-1181
pubmed: 31449138
Radiol Med. 2016 Feb;121(2):122-31
pubmed: 26345332
Dig Surg. 2016;33(4):351-9
pubmed: 27216160
World J Gastroenterol. 2017 Jul 14;23(26):4767-4778
pubmed: 28765698
Langenbecks Arch Surg. 2007 Jan;392(1):55-60
pubmed: 17089173
Radiology. 2017 Feb;282(2):585-597
pubmed: 27604035
Radiol Med. 2018 Mar;123(3):185-190
pubmed: 29086381
Radiol Med. 2020 Oct;125(10):907-917
pubmed: 32274620
Radiol Med. 2016 May;121(5):409-30
pubmed: 27075018
Scand J Gastroenterol. 2017 Nov;52(11):1165-1171
pubmed: 28687047
JOP. 2006 Jan 11;7(1):74-8
pubmed: 16407624
Eur J Surg Oncol. 2019 Nov;45(11):2166-2172
pubmed: 31227340
Radiol Med. 2014 Jan;119(1):33-40
pubmed: 24234185
Curr Probl Cancer. 2013 Sep-Oct;37(5):262-5
pubmed: 24331180
Pancreatology. 2017 Nov - Dec;17(6):962-966
pubmed: 29037917
Radiol Med. 2014 Jul;119(7):499-511
pubmed: 25024061
J Surg Oncol. 2017 May;115(6):711-717
pubmed: 28185295
Int J Hyperthermia. 2018;35(1):398-418
pubmed: 30428728
World J Clin Oncol. 2012 Jan 10;3(1):12-4
pubmed: 22247824
Ann Surg. 2015 Sep;262(3):486-94; discussion 492-4
pubmed: 26258317
J Vasc Interv Radiol. 2020 Jan;31(1):162-168.e7
pubmed: 31530492
Radiology. 2009 Apr;251(1):1-2
pubmed: 19332838
Oncologist. 2019 Oct;24(10):e990-e1005
pubmed: 31217342
Cancers (Basel). 2019 Jul 12;11(7):
pubmed: 31336859
World J Gastrointest Surg. 2015 Apr 27;7(4):52-9
pubmed: 25914783
Med Biol Eng Comput. 2017 Jul;55(7):1123-1127
pubmed: 28078482
Front Oncol. 2020 Nov 27;10:560952
pubmed: 33330028
Radiol Med. 2014 Jul;119(7):451-61
pubmed: 24894923
Tech Vasc Interv Radiol. 2020 Jun;23(2):100675
pubmed: 32591191
J Neuroendocrinol. 2021 Feb;33(2):e12936
pubmed: 33474756
Endoscopy. 2016;48 Suppl 1:E144-5
pubmed: 27081874
Lancet Oncol. 2017 Jun;18(6):770-778
pubmed: 28495639
J Natl Compr Canc Netw. 2019 May 1;17(5.5):603-605
pubmed: 31117041
J Vasc Interv Radiol. 2013 Oct;24(10):1513-20
pubmed: 24070507